$5.810
+0.071 (+1.22%)At close
LFWD News
LFWD Events
Rewalk Robotics LTD Trading Halted Due to Volatility
Rewalk Robotics LTD trading halted, volatility trading pause
Lifeward Appoints Josh Hexter as Interim CEO
Lifeward announced the appointment of Josh Hexter as interim CEO effective September 1 and Rami Aviram as CFO effective November 1. Hexter succeeds Mark Grant, who has chosen to leave Lifeward to pursue other opportunities after leading the development and implementation of the company's current commercial strategy. Grant will serve as a consultant with the company through September 30 to work closely with Hexter and the leadership team to ensure a transition.
Company Not Selling 2.07M Ordinary Shares
This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.07M ordinay shares. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
Lifeward Appoints Keith Rose as Chief Medical Officer
Lifeward announced the appointment of Keith Rose as chief medical officer. Rose, who previously served as VP, medical affairs and medical director, Neurosciences at Lifeward, will lead the company's global medical strategy.
Lifeward Files to Sell 7.26M Ordinary Shares
Lifeward files to sell 7.26M ordinary shares for holders
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.